Heat shock protein 90-alpha (Hsp90α)

Where the papers sit

21 papers from the last 6 months study Heat shock protein 90-alpha (Hsp90α) directly · updated from PubMed 12 Oct 2026

• HSP90AA1 Therapeutic Targeting

  Network pharmacology is moving HSP90AA1 from a chaperone marker toward a druggable node in neurodegeneration and cancer. In Alzheimer’s disease, integrated analyses connect it with oxidative stress, reactive oxygen species and PGC-1α-linked mitochondrial function, while sevoflurane studies focus on hippocampal mitophagy. FDA-approved inhibitors and natural-product formulas are being prioritized through docking, ADMET and molecular-dynamics analyses. Disease-specific validation and effects on endothelial or cognitive outcomes remain open.

  6 papers · 28.6%

• HSP90AA1 Disease Signatures

  Integrated omics and machine learning are positioning HSP90AA1 within disease-risk and treatment-response networks rather than treating it as an isolated target. In hepatocellular carcinoma, HSP90AA1 appears in HIF-1α-related prognostic signatures alongside EGFR and beta-catenin-linked transcriptional programs. Quercetin, nutraceutical formulas and environmental chemicals are being used to probe these multi-target networks, with inflammatory signaling extending the framework to rheumatoid arthritis. Experimental validation and improved patient stratification remain the main unresolved steps.

  6 papers · 28.6%

• HSP90 Inhibition Across Diseases

  HSP90 inhibition is being tested across acute myeloid leukemia, triple-negative breast cancer and viral infection rather than confined to one disease. TP53-mutant AML with ribosomal gene loss shows a defined vulnerability through impaired protein translation, while marine and bakuchiol-derived inhibitors seek selective cytotoxicity and synergy. Tanespimycin also suppresses SARS-CoV-2 main protease activity, extending chaperone targeting beyond tumors. Pharmacologic blockade recurs across the cluster, but clinical translation and disease-specific selectivity remain unresolved.

  5 papers · 23.8%

• HSP90 Drug Development

  Drug development is broadening HSP90 targeting from cytotoxic inhibitors to orally active agents and molecular imaging. Evodiamine-derived conjugates are being optimized for colon-cancer treatment, while 740 Y-P and HSP90AB1 studies examine growth signaling in oral cancer. A labeled inhibitor is being developed as a PET/SPECT tracer, adding target visualization to therapy. Outside cancer, HSP90-mediated NLRP3 stability links the target to ox-LDL-driven steatohepatitis, but therapeutic value remains preclinical.

  4 papers · 19%